Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Moderna stock | 73.94

Own Moderna stock in just a few minutes.

Fact checked

Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. But this vaccine has yet to be approved by the FDA and may not be available to the general public for months. Here’s how to buy Moderna stock.

How to buy shares in Moderna

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Moderna. Find the stock by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$73.94, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Moderna. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Moderna’s COVID-19 vaccine

On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.

Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.

Moderna is working towards emergency-use approval with the US Food and Drug Administration (FDA). The FDA requires coronavirus vaccines to hold an efficacy rate of at least 50% to be approved.
In response to Moderna’s announcement, its stock spiked by over 8%, the Dow Jones Industrial Average rose by nearly 400 points and the S&P 500 set a record high above 3,615 points.

Moderna vs. Pfizer

Both Moderna and Pfizer have made numerous news headlines as they work to develop effective coronavirus vaccines. But how do their vaccines compare? Here’s how these COVID-19 vaccines stack up.

Moderna Pfizer
Type of vaccine Messenger RNA (mRNA) Messenger RNA (mRNA
Efficacy rate 94.5% 95%
Trial size 30,000 people 43,538 people
Number of doses 2 shots, 28 days apart 2 shots, 21 days apart
Storage -20°C -70°C
Production Up to 20 million doses by the end of 2020 Up to 50 million doses by the end of 2020
Years in business 10 171
Number of manufactured drugs 0 300+

How has coronavirus impacted Moderna's share price?

Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.

Its last market close was USD$73.94, which is 75.34% up on its pre-crash value of USD$18.23 and 312.84% up on the lowest point reached during the March crash when the shares fell as low as USD$17.91.

If you had bought USD$1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth USD$1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,628.24.

Moderna share price

Use our graph to track the performance of MRNA stocks over time.

Moderna shares at a glance

Information last updated 2020-11-26.
Latest market close USD$73.94
52-week range USD$17.68 - USD$109.29
50-day moving average USD$77.7708
200-day moving average USD$70.1764
Wall St. target price USD$106.13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.348

Buy Moderna shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Moderna price performance over time

Historical closes compared with the close of $73.94 from 2020-10-16

1 week (2020-11-19) -20.30%
1 month (2020-10-26) 5.27%
3 months (2020-08-26) 4.88%
6 months (2020-05-26) 28.12%
1 year (2019-11-26) 263.70%
2 years (2018-11-22) N/A
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Moderna financials

Revenue TTM USD$246.7 million
Gross profit TTM USD$-436,100,000
Return on assets TTM -12.37%
Return on equity TTM -29.81%
Profit margin -242.34%
Book value $6.98
Market capitalisation USD$43.2 billion

TTM: trailing 12 months

Shorting Moderna shares

There are currently 25.2 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 7.7% down from 27.3 million last month.

There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.

Moderna's "short interest ratio" (SIR)

Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 8.6 million). Moderna's SIR currently stands at 2.95. In other words for every 100,000 Moderna shares traded daily on the market, roughly 2950 shares are currently held short.

However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 60 shares are currently held short) or 0.0812% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 81 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.

Find out more about how you can short Moderna stock.

Moderna share dividends

We're not expecting Moderna to pay a dividend over the next 12 months.

Moderna overview

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site